Collegium Pharmaceutical Plans to Release Financial Results
Collegium Pharmaceutical, Inc. (NASDAQ: COLL) has made a significant announcement regarding its upcoming financial performance. The company is set to report its second quarter financial results for the year 2025 before the market's opening on Thursday, August 7, 2025. This anticipated report will highlight the company's progress and financial health as it continues its mission to enhance patient well-being.
Conference Call Details
Following the financial results announcement, Collegium will hold a live conference call and webcast at 8:00 a.m. ET. To participate in the conference call, interested parties can dial (877) 407-8037 if calling from the U.S., or (201) 689-8037 from international locations, making sure to reference the "Collegium Pharmaceutical Q2 2025 Earnings Call." For those who prefer to listen online, an audio webcast will be available in the Investors section of the company’s website.
Webcast Replay
For anyone unable to attend the live session, a replay of the webcast will be accessible on Collegium's website approximately two hours after the event concludes. This ensures that all stakeholders, irrespective of their availability, can stay informed about the company's performance and insights shared during the call.
About Collegium Pharmaceutical
Collegium Pharmaceutical is dedicated to developing effective solutions for patients with serious medical conditions. The company prides itself on having an exceptional portfolio that focuses on responsible pain management, alongside its recent acquisition of Jornay PM, a key treatment for ADHD that expands its footprint into neuropsychiatry. By strategically growing its commercial offerings, Collegium aims to leverage Jornay PM as a major growth driver while ensuring that its capital is deployed prudently.
Commitment to Patients
Committed to enhancing lives, Collegium is continually exploring ways to address the pressing health needs of patients. The company’s strategic focus not only revolves around expanding its product line but also emphasizes the importance of responsible use of medications in managing pain and neuropsychiatric conditions.
Contact Information for Investors
For investors seeking additional information or clarifications about Collegium's operations and future plans, the company has made it easy to connect with their investor relations team. Ian Karp, Head of Investor Relations, can be reached via email at ir@collegiumpharma.com. Additionally, Danielle Jesse, Director of Investor Relations, is also available at the same email address for further inquiries.
Frequently Asked Questions
What is the date for Collegium's Q2 2025 earnings report?
Collegium is reporting its Q2 2025 earnings on August 7, 2025.
How can I participate in the earnings call?
You can join by dialing (877) 407-8037 in the U.S. or (201) 689-8037 internationally.
Is there a way to access the earnings call after it has occurred?
Yes, a replay will be available on Collegium's website about two hours after the call ends.
What does Collegium Pharmaceutical focus on?
The company focuses on developing effective medications for pain management and treatments for ADHD.
Who can I contact for investor inquiries?
You can reach Ian Karp or Danielle Jesse at ir@collegiumpharma.com.
